Open AccessA double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis
Author(s) -
Lin Cai,
Gen-Hui Chen,
Qianjin Lu,
Min Zheng,
Yuzhen Li,
Jin Chen,
Jie Zheng,
Furen Zhang,
Jinming Yu,
Sen Yang,
Fuqiu Li,
Shengxiang Xiao,
Qiuning Sun,
Jinhua Xu,
XingHua Gao,
Hong Fang,
Tianwen Gao,
Hao Fei,
Quanzhong Liu,
Yating Tu,
Ruoyu Li,
Baoxi Wang,
Di Deng,
Qingshan Zheng,
Hongxia Liu,
Jianzhong Zhang
Publication year - 2020
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000001221
Subject(s) - medicine , calcipotriol , placebo , plaque psoriasis , psoriasis , adverse effect , psoriasis area and severity index , irritation , dermatology , clinical trial , randomized controlled trial , gastroenterology , placebo group , pathology , alternative medicine , immunology
Benvitimod cream, a novel synthetic small molecule, was effective in treating mild-to-moderate plaque psoriasis. We conducted a phase III clinical trial to assess the efficacy and safety of benvitimod cream in patients with mild-to-moderate plaque psoriasis.